KCA-1490 

KCA-1490 is a dual PDE3/4 inhibitor with IC₅₀ values of 369 nM and 42 nM, respectively. KCA-1490 exhibits potent bronchodilatory and anti-inflammatory activity. KCA-1490 suppresses Histamine (HY-B1204)-induced bronchoconstriction in vivo, which is promising for research of asthma and chronic obstructive pulmonary disease (COPD)^[1][2][3].

326.27

C₁₄H₁₃F₃N₄O₂

909719-71-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ochiai K, et al. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5833-8.  [Content Brief]

  [2]. Ochiai K, et al. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett. 2013 Jan 1;23(1):375-81.  [Content Brief]

  [3]. Jin J, et al. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes. Int J Mol Sci. 2023 Jul 15;24(14):11518.  [Content Brief]